The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis
Publication in refereed journal


Times Cited
Altmetrics Information
.

Other information
AbstractObjectives: Estimate the epidermal growth factor receptor (EGFR) mutation prevalence in all non-small cell lung cancer (NSCLC) patients and patient subgroups.

Results: A total of 456 studies were included, reporting 30,466 patients with EGFR mutation among 115,815 NSCLC patients. The overall pooled prevalence for EGFR mutations was 32.3% (95% CI 30.9% to 33.7%), ranging from 38.4% (95% CI: 36.5% to 40.3%) in China to 14.1% (95% CI: 12.7% to 15.5%) in Europe. The pooled prevalence of EGFR mutation was higher in females (females vs. males: 43.7% vs. 24.0%; OR: 2.7, 95% CI: 2.5 to 2.9), non-smokers (non-smokers vs. past or current smokers: 49.3% vs. 21.5%; OR: 3.7, 95% CI: 3.4 to 4.0), and patients with adenocarcinoma (adenocarcinoma vs. non-adenocarcinoma: 38.0% vs. 11.7%; OR: 4.1, 95% CI: 3.6 to 4.8).

Materials and Methods: PubMed, EMBASE, and the Cochrane Library were searched to June 2013. Eligible studies reported EGFR mutation prevalence and the association with at least one of the following factors: gender, smoking status and histology. Random-effects models were used to pool EGFR mutation prevalence data.

Conclusion: This study provides the exact prevalence of EGFR mutations in different countries and NSCLC patient subgroups.
All Author(s) ListYue-Lun Zhang, Jin-Qiu Yuan, Kai-Feng Wang, Xiao-Hong Fu, Xiao-Ran Han, Diane Threapleton, Zu-Yao Yang, Chen Mao, Jin-Ling Tang
Journal nameOncotarget
Year2016
Month10
Day12
Volume Number7
Issue Number48
Pages78985 - 78993
ISSN1949-2553
LanguagesEnglish-United Kingdom

Last updated on 2020-15-08 at 00:55